IV期黑色素瘤患者血清25-羟维生素D水平降低。

Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients.

作者信息

Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, Tilgen W, Reichrath J

机构信息

Department of Dermatology, The Saarland University Hospital, Homburg, Germany.

出版信息

Anticancer Res. 2009 Sep;29(9):3669-74.

PMID:19667163

Abstract

BACKGROUND

Reduced serum 25-hydroxyvitamin D3 (25(OH)D) levels are associated with an increased incidence and an unfavorable outcome of various types of cancer. However, the influence of serum 25(OH)D on the incidence and outcome of patients with malignant melanoma is unknown.

PATIENTS AND METHODS

The association between serum 25(OH)D levels and clinical and histopathological data among 205 patients with malignant melanoma was examined. Additionally, 141 healthy controls were investigated. All the blood samples were taken between October and April to minimize seasonal variations; basal serum 25(OH)D levels were analyzed using the LIAISON 25-OH Vitamin D-Assay (DiaSorin, Dietzenbach, Germany). The study started in 1997. The patients were observed until death or March 2007, whichever came first.

RESULTS

Serum 25(OH)D levels were significantly reduced in stage IV melanoma patients as compared to stage I melanoma patients (p=0.006). A trend toward a greater tumor thickness of the primary cutaneous melanomas was seen in the patients with low (<10 ng/ml) serum 25(OH)D levels (median: 2.55 mm) as compared to those with 25(OH)D serum levels >20 ng/ml (median: 1.5 mm), although this difference was not statistically significant (p=0.078). The patients with low 25(OH)D serum levels (<10 ng/ml) had earlier distant metastatic disease (median: 24.37 months) as compared to those with 25(OH)D serum levels >20 ng/ml (median: 29.47 months), although this difference was also not statistically significant (p=0.641).

CONCLUSION

Among the patients with malignant melanoma, significantly reduced serum 25(OH)D levels were found in the stage IV patients as compared to stage I patients, and those with low 25(OH)D serum levels (<10 ng/ml) may develop earlier distant metastatic disease compared to those with higher 25(OH)D serum levels (>20 ng/ml). Further study of the vitamin D pathway and its influence on pathogenesis and progression of malignant melanoma is warranted.

摘要

背景

血清25-羟基维生素D3（25(OH)D）水平降低与各类癌症的发病率增加及不良预后相关。然而，血清25(OH)D对恶性黑色素瘤患者发病率及预后的影响尚不清楚。

患者与方法

检测了205例恶性黑色素瘤患者血清25(OH)D水平与临床及组织病理学数据之间的关联。此外，还对141名健康对照者进行了调查。所有血样均在10月至4月采集，以尽量减少季节变化的影响；使用LIAISON 25-OH维生素D检测法（德国迪岑巴赫的索林公司）分析基础血清25(OH)D水平。该研究始于1997年。对患者进行观察，直至死亡或2007年3月，以先到者为准。

结果

与I期黑色素瘤患者相比，IV期黑色素瘤患者的血清25(OH)D水平显著降低（p = 0.006）。血清25(OH)D水平低（<10 ng/ml）的患者，其原发性皮肤黑色素瘤的肿瘤厚度有增加趋势（中位数：2.55 mm），而血清25(OH)D水平>20 ng/ml的患者肿瘤厚度中位数为1.5 mm，尽管这种差异无统计学意义（p = 0.078）。血清25(OH)D水平低（<10 ng/ml）的患者发生远处转移疾病的时间较早（中位数：24.37个月），而血清25(OH)D水平>20 ng/ml的患者中位数为29.47个月，尽管这种差异也无统计学意义（p = 0.641）。